# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-052069
Filing Date
2023-04-28
Accepted
2023-04-28 07:30:11
Documents
9
Period of Report
2023-06-06

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2312680-2_def14a.htm | DEF 14A | 1214193
2 | GRAPHIC | lg_carismatherapeutics-4c.jpg | GRAPHIC | 101495
3 | GRAPHIC | sg_skwet-bw.jpg | GRAPHIC | 28491
4 | GRAPHIC | sg_sanfordzweifach-bw.jpg | GRAPHIC | 23285
5 | GRAPHIC | lg_mackenziepartners-bw.jpg | GRAPHIC | 31267
6 | GRAPHIC | bc_tsr-4c.jpg | GRAPHIC | 122925
7 | GRAPHIC | bc_netincome-4c.jpg | GRAPHIC | 111648
8 | GRAPHIC | px_page01-4c.jpg | GRAPHIC | 1076045
9 | GRAPHIC | px_page02-4c.jpg | GRAPHIC | 732894
| Complete submission text file | 0001104659-23-052069.txt |  | 4013719

Mailing Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 200 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: PA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36296 | Film No.: 23860179
SIC: 2834 Pharmaceutical Preparations